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Increased systemic levels of myeloperoxidase (MPO) are associated with the risk of coronary artery disease
(CAD). To identify the genetic factors that are associated with circulating MPO levels, we carried out a
genome-wide association study (GWAS) and a gene-centric analysis in subjects of European ancestry and
African Americans (AAs). A locus on chromosome 1q31.1 containing the complement factor H (CFH) gene
was strongly associated with serum MPO levels in 9305 subjects of European ancestry (lead SNP rs800292;
P 5 4.89 3 10241) and in 1690 AA subjects (rs505102; P 5 1.05 3 1028). Gene-centric analyses in 8335 subjects
of European ancestry additionally identified two rare MPO coding sequence variants that were associated with
serum MPO levels (rs28730837, P 5 5.21 3 10212; rs35897051, P 5 3.32 3 1028). A GWAS for plasma MPO levels
in9260Europeanancestrysubjects identifiedachromosome17q22regionnearMPO thatwassignificantlyasso-
ciated (lead SNP rs6503905; P 5 2.94 3 10212), but the CFH locus did not exhibit evidence of association with
plasma MPO levels. Functional analyses revealed that rs800292 was associated with levels of complement pro-
teins in serum. Variants at chromosome 17q22 also had pleiotropic cis effects on gene expression. In a case–
control analysis of ∼80 000 subjects from CARDIoGRAM, none of the identified single-nucleotide polymorph-
isms (SNPs) were associated with CAD. These results suggest that distinct genetic factors regulate serum
and plasma MPO levels, which may have relevance for various acute and chronic inflammatory disorders. The
clinical implications for CAD and a better understanding of the functional basis for the association of CFH
and MPO variants with circulating MPO levels require further study.
INTRODUCTION
Myeloperoxidase (MPO) is a lysosomal enzyme stored within
the azurophilic granules of circulating neutrophils, monocytes
and tissue macrophages (1). It is released upon leukocyte (both
neutrophils and monocytes) activation and generates various re-
active oxidants and free radicals that play important roles in
killing invading parasites and pathogens. The same MPO-
derived oxidants have also been implicated in the formation of
atherogenic low-density lipoprotein particles, the development
of dysfunctional high-density lipoprotein (HDL) particles, cata-
lytic consumption of nitric oxide, vascular endothelial injury,
and development of atherosclerotic plaque and its clinical seque-
lae (2–4). Furthermore, high circulating levels of MPO, as mea-
sured in serum, plasma or leukocytes, predict major adverse
cardiac events in healthy individuals, and in patients with coron-
ary artery disease (CAD) or heart failure (5–8). In addition,
MPO has been shown to be positively correlated with traditional
and inflammatory CAD risk factors such as age, sex, blood pres-
sure, body mass index, cigarette smoking, glucose, white blood
cell count and C-reactive protein levels (9–11).
Heritability estimates for serum MPO range from 25 to 30%
(9,12), suggesting that variation in serum MPO levels has a sig-
nificant genetic component. Loss-of-function mutations in the
MPO gene that result in total or partial MPO deficiency are
rare in the population (1 in 2000) (13,14) and have been asso-
ciated with increased susceptibility to infection as well as protec-
tion from CAD (15). Candidate gene studies have also identified
common variants of MPO that have been associated with CAD as
well as circulating MPO levels (16–19). However, a more com-
plete understanding of the genetic factors controlling circulating
MPO levels is still lacking. Therefore, the aim of the present
study was to use large-scale unbiased genome-wide and targeted
gene-centric analyses to identify loci controlling serum and
plasma MPO levels and to determine whether MPO-associated
variants influence the risk of CAD. To our knowledge, these ana-
lyses would represent the first genome-wide association study
(GWAS) for circulating MPO levels.
RESULTS
GWAS for serum MPO levels
We first carried out a meta-analysis of GWAS data for serum
MPO levels in 9305 subjects of European ancestry. The charac-
teristics of the Cleveland Clinic GeneBank (GeneBank), the
Coronary Artery Risk Development in Young Adults
(CARDIA) Study, Cardiovascular Health Study (CHS), and Fra-
mingham Heart Study (FHS) cohorts and datasets used for these
analyses are summarized in Table 1. The observed variability in
MPO levels, which could have also been influenced by either
sample storage-related effects or acute minor infections at the
time of blood collection, made it difficult to harmonize MPO
assays across cohorts. Therefore, single-nucleotide polymorph-
ism (SNP) association results were combined using an effective
sample-weighted Z-score meta-analysis method. The quantile–
quantile (Q–Q) and Manhattan plots for serum MPO levels are
presented in Figure 1A and B. The observed genomic control
factors in the four discovery cohorts were near unity
(GeneBank¼ 0.999; CHS ¼ 1.015; FHS ¼ 1.004; CARDIA ¼
1.004), suggesting that the GWAS results were not strongly con-
founded by underlying population stratification. SNPs at three
loci on chromosomes 1q31.3, 6p21.32 and 20p13 exceeded the
pre-specified threshold for genome-wide significance (5.0 ×
1028). The characteristics of the lead SNPs at these three loci
and their association with serum MPO levels are summarized
3382 Human Molecular Genetics, 2013, Vol. 22, No. 16
in Table 2 and Supplementary Material, Table S2. The lead SNP
at 1q31.3, rs800292 (P ¼ 4.89 × 10241), is a non-synonymous
Val62Ile (GTA.ATA) substitution in the complement factor
H gene (CFH) with a minor allele frequency (MAF) of 0.23 in
Europeans. The CFH-CFHR3-CFHR1 genomic region on
chromosome 1q31.3 contains several other variants that were
also significantly associated with serum MPO levels, which
show varying levels of linkage disequilibrium (LD) with
rs800292 (Fig. 2A). Of note, rs800292 is in low LD with other
CFH variants, such as rs1061170 (Tyr402His), previously iden-
tified as susceptibility alleles for other disease phenotypes (Sup-
plementary Material, Table S3). To determine whether the other
SNPs in this region represent independent association signals,
we also ran analyses taking into the account the effect of the
lead SNP rs800292. These conditional analyses revealed that
the strength of the association for the other SNPs in this region
was attenuated and did not exceed the genome-wide threshold
for significance (Supplementary Material, Table S3). Using the
GeneBank cohort, we also analyzed the loci associated with
serum MPO levels with further adjustment for CAD, history of
hypertension, lipid levels, or white blood cell count. However,
these additional adjustments did not alter the effect estimates
or P-values compared with those adjusted for only age and sex
(data not shown).
The locus on chromosome 6p21.32 contains several immune
system related genes, including complement component 2 (C2)
and HLA (Fig. 2B). The lead SNP (rs3134931; P ¼ 1.49 ×
1028) is located within intron 2 of NOTCH4 and is not in
strong LD (r2 , 0.4) with any of the other 130 variants in this
region that demonstrate suggestive (P , 5.0 × 1026) associ-
ation with serum MPO levels (Fig. 2B). One SNP at chromosome
20p13, which is not in LD (r2 , 0.2) with other variants in this
region, was also significantly associated with serum MPO
levels (rs6042507; P ¼ 4.30 × 1028) (Fig. 2C). This SNP
encodes a non-synonymous Ala215Glu substitution
(GCG.GAG) in exon 3 of the signal-regulatory protein beta 2
gene (SIRPB2), which belongs to the family of genes expressed
predominantly in neutrophils and monocytes. Suggestive evi-
dence of association with serum MPO levels was also observed
on chromosome 1q42.13 (rs2144300; P ¼ 2.52 × 1026)
containing N-actetylgalactosaminyltransferase 2 (GALNT2)
and a region on 8p21.3 (rs1390943; P ¼ 9.38 × 1027) contain-
ing the vacuolar proton ATPase subunit B (ATP6V1B) and
leucine zipper putative tumor suppressor 1 (LZTS1) genes
(Fig. 1B; Table 2; Supplementary Material, Table S2).
Gene-centric analyses for serum MPO levels
Using CARe data from the CARDIA (n ¼ 1262), CHS (n ¼
3085) and FHS (n ¼ 2660) cohorts, as well as 1328 additional
subjects of European ancestry from the Monitoring of Trends
and Determinants in Cardiovascular Disease Cooperative
Health Research in the Region of Augsburg (MONICA/
KORA) cohort, we carried out gene-centric analyses using the
IBC 50K custom SNP array. This chip has dense SNP coverage
for 2100 CAD candidate genes, including CFH, C2 and
GALNT2 (but not NOTCH4 or SIRBP2) and contains specific
rare amino acid substitutions that would otherwise not be cap-
tured by imputed GWAS datasets. As a result, the gene-centric
analyses allowed us to validate and fine map a subset of the
loci identified in the GWAS meta-analysis, as well as potentially
identify other variants associated with serum MPO levels.
As shown in Table 2 and Supplementary Material, Table S4, a
strong association of serum MPO levels was observed with var-
iants in CFH where the lead SNPs yielded P-values of 6.65 ×
10243 (rs6680396) and 4.74 × 10242 (rs505102). The rs6680396
and rs505102 variants are in high LD (r2 ¼ 0.87) with each
other in subjects of European descent (based on the 1000
Genome Project CEU data), and also with the lead SNP identified
in the GWAS for serum MPO levels (rs800292). A combined
analysis of the CFH locus using all available unique individuals
in the GWAS and IBC datasets, including the GeneBank cohort
(combined n ¼ 10 524), further strengthened the association of
rs6680396 with serum MPO levels (P ¼ 9.34 × 10245). The
gene-centric analyses also identified an SNP on chromosome
6p21.32 (rs9332739) in C2 that was strongly associated with
serum MPO levels (P ¼ 4.83 × 10210) (Table 2; Supplementary
Material, Table S4). Rs9332739 (MAF ¼ 0.044) encodes a non-
synonymous Glu318Asp (GAG.GAC) substitution in C2 and is
located 287 kb proximal to the lead SNP (rs3134931) in
Table 1. Description of cohorts and datasets used in this study
Cohort Ethnicity N Age (year) M/F MPO levels
(pmol/l)
Source (Assay) Genotyping platform Number
of SNPs
GeneBank European 2189 62.5+11.2 1554/635 760.1+719.5 Serum (CardioMPO) Affymetrix 6.0 (Imputed) 2 421 770
European 2191 62.5+11.2 1555/636 225.5+293.9 Plasma (CardioMPO) Affymetrix 6.0 (Imputed) 2 421 770
CHS European 2667 71.9+5.0 1028/1639 345.6+280.1 Serum (CardioMPO) Illumina CNV370 (Imputed) 2 397 181
European 3085 72.2+5.2 1327/1758 353.1+318.6 Serum (CardioMPO) IBCv2 SNP array 46 423
AAs 643 72.8+5.6 238/405 382.1+330.7 Serum (CardioMPO) IBCv2 SNP array 47 046
FHS European 2940 61.0+9.5 1359/1581 334.3+218.8 Serum (OXIS) Affymetrix 500 K (Imputed) 2 486 777
European 2660 61.0+9.5 1218/1442 335.4+220.1 Serum (OXIS) IBCv2 SNP array 46 930
CARDIA European 1509 25.6+3.3 701/808 137.0+97.0 Serum (CardioMPO) Affymetrix 6.0 (Imputed) 2 409 479
European 1262 40.7+3.3 580/682 139.1+98.2 Serum (CardioMPO) IBCv2 SNP array 46 506
AAs 1047 39.5+3.8 440/607 108.4+85.6 Serum (CardioMPO) IBCv2 SNP array 46 346
MONICA/
KORA
European 1328 52.7+10.6 700/628 134.2+67.5 Serum (Mercodia) IBCv2 SNP array 44 142
GHS I European 2996 55.8+10.9 1453/1543 327.7+189.6 Plasma (CardioMPO) Affymetrix 6.0 (Imputed) 2 614 503
GHS II European 1178 55.1+10.9 589/589 290.9+132.7 Plasma (CardioMPO) Affymetrix 6.0 (Imputed) 2 612 433
LURIC1 European 794 59.9+12.0 523/271 241.2+71.0 Plasma (Immundiagnostik) Affymetrix 500 K (Imputed) 5 979 070
LURIC2 European 2100 63.5+10.0 1488/610 174.0+61.6 Plasma (Immundiagnostik) Affymetrix 6.0 (Imputed) 6 420 716
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NOTCH4 that was identified in the GWAS for serum MPO levels
(Fig. 2B). However, in an analysis that included GeneBank (com-
bined n¼ 10 524) the association of rs9332739 with serum MPO
levels was less significant than in the IBC analyses (P ¼ 1.76 ×
1027), as this variant was not associated with serum MPO levels
in GeneBank (P¼ 0.39). The gene-centric analyses also identified
two rare variants (MAF 1%) of MPO (the structural gene for the
enzyme) on chromosome 17q22 that were significantly associated
with serum MPO levels (Table 2; Supplementary Material,
Table S4). One SNP encodes an Ala332Val substitution
(rs28730837; GCG.GTG; P¼ 5.21 × 10212) and the other
interrupts the first position (AG.CG) of the 3′ splice junction of
intron 11 (rs35897051; P ¼ 3.32 × 1028). Since these rare
variants were specifically included on the IBC array and not
present in any of the imputed GWAS datasets, we were not able
to carry out a combined analysis with all subjects. In addition to
these rare variants, another SNP (rs8081967, MAF¼ 0.36)
located 724 kb telomeric to MPO in intron 23 of TRIM37 exhib-
ited suggestive evidence of association (P¼ 2.13 × 1026) with
serum MPO levels (Table 2; Supplementary Material, Table S4).
Of note, rs8081967 also demonstrated suggestive evidence in the
GWAS analyses of serum MPO levels (P ¼ 6.59 × 1025),
which reached significance (P¼ 1.44 × 1028) in an analysis
using all unique subjects in the GWAS and IBC datasets (com-
bined n¼ 10 524). In addition, we also observed suggestive evi-
dence of association with rs2144300 in GALNT2 (P¼ 2.52 ×
Figure 1. Results of the GWAS for serum MPO levels in subjects of European ancestry. The Q–Q (A) and Manhattan (B) plots are shown for the meta-analysis of 9305
subjects from the GeneBank, CHS, FHS and CARDIA cohorts.
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1027) in the IBC analyses (Table 2; Supplementary Material,
Table S4), but this association did not achieve genome-wide sig-
nificance (P¼ 2.68 × 1027) in a combined analysis with all
unique subjects in the GWAS and IBC datasets (n¼ 10 524).
Replication of loci for serum MPO levels in African
Americans (AAs)
To replicate the association findings observed with serum MPO
levels and determine whether the loci have similar effects on
other ethnicities, we used IBC SNP array data available in
1690 African Americans (AAs) from the CARDIA (n ¼ 1047)
and CHS (n ¼ 643) cohorts. Consistent with the results on sub-
jects of European ancestry, rs505102 in CFH was significantly
associated (P ¼ 1.05 × 1028) with serum MPO levels in AAs
(Table 2; Supplementary Material, Table S5), thus providing in-
dependent validation of this locus in a different ethnic group. The
IBC analyses in AAs also yielded suggestive evidence for asso-
ciation of serum MPO levels with rs2814778 (P ¼ 6.48 × 1028)
(Table 2; Supplementary Material, Table S5), which is located in
the 5′ UTR of the Duffy blood group antigen gene (DARC) on
chromosome 1q23.3. Because rs2814778 is an important deter-
minant of circulating neutrophil count in AAs, we further
adjusted this analysis for white blood count. The association
was strongly attenuated (P ¼ 0.02), suggesting that the associ-
ation of rs2814778 with serum MPO in AAs is largely mediated
through the number of circulating neutrophils. In addition to val-
idating the association of CFH with serum MPO levels observed
in subjects of European ancestry, there was supportive evidence
in AAs for association of serum MPO levels with rs9332739 in
C2 (P ¼ 0.0045) and the rare Ala332Val (rs28730837) substitu-
tion in MPO (P ¼ 0.061) (Supplementary Material, Table S5),
but not with the other variant in MPO (rs35897051; P ¼ 0.93)
or with rs2144300 in GALNT2 (P ¼ 0.77).
GWAS for plasma MPO levels
We next carried out a GWAS meta-analysis for plasma MPO
levels in subjects of European ancestry from the GeneBank,
Gutenberg Health Study (GHS), and Ludwigshafen Risk and
Cardiovascular Health (LURIC) cohorts (total n ¼ 9260). The
Q–Q and Manhattan plots for the plasma MPO analyses are
shown in Figure 3A and B, and the genomic control factors
were 0.999, 1.008, 0.980, 0.970 and 0.991 for the GeneBank
(n ¼ 2191), GHS I (n ¼ 2997), GHS II (n ¼ 1178), LURIC1
(n ¼ 794) and LURIC2 cohorts (n ¼ 2100), respectively. The
most significant locus for plasma MPO levels mapped to
chromosome 17q22 near MPO with the lead SNP (rs6503905)
yielding a P-value of 2.94 × 10212 (Fig. 3B, Table 2; Supple-
mentary Material, Table S6). The variant, rs6503905 (MAF ¼
0.37), encodes a putative synonymous substitution
(GCG.GCA; Ala14Ala) in the predicted gene C17orf71,
which is located 930kb telomeric of MPO. As shown in
Figure 3C and Supplementary Material, Table S6, several
other SNPs spanning an 1 Mb interval in this region and
within different LD blocks were also significantly associated
with plasma MPO levels, including rs9911753 (P ¼ 1.51 ×
1029), rs2680701 (P ¼ 4.98 × 10210), and rs12940923 (P ¼
3.85 × 1029). However, rs6503905 is only in moderate LD
with rs9911753 (r2 ¼ 0.28) and completely unlinked to
rs2680701 and rs12940923 (r2 , 0.1 for each SNP). In addition,
rs9911753 is in strong LD (r2 ¼ 0.87) with rs8081967, which
was identified in our combined GWAS/IBC analyses for serum
MPO levels (Table 2). We next re-performed the analyses condi-
tioned on rs6503905, rs9911753, rs2680701 or rs12940923. The
Table 2. Significant and suggestive loci associated with decreased circulating MPO levels in the GWAS and gene-centric analyses




EAF Beta (SE) P-value MPO
Levels
Ethnicity Analysis I2-statistic
1q31.3 (CFH) rs800292 194 908 856 A/G 0.23 20.15 (0.01) 4.89 × 10241 Serum European GWAS 89.7
6p21.32
(NOTCH4-C2-HLA)
rs3134931 32 298 598 T/C 0.73 20.05 (0.01) 1.49 × 10208 Serum European GWAS 0
20p13 (SIRPB2) rs6042507 1 407 060 A/C 0.11 20.09 (0.02) 4.30 × 10208 Serum European GWAS 38.5
1q42.13 (GALNT2) rs2144300 228 361 539 C/T 0.39 20.05 (0.01) 2.52 × 1026 Serum European GWAS 34.5
8p21.3
(ATP6V1B2-LZTS1)
rs1390943 20 126 170 G/T 0.33 20.05 (0.01) 9.38 × 1027 Serum European GWAS 30.9
1q31.3 (CFH) rs6680396 194 899 093 G/A 0.22 20.13 (0.01) 6.65 × 10243 Serum European IBC 88.5
6p21.32 (C2) rs9332739 32 011 783 C/G 0.044 20.12 (0.02) 4.83 × 10210 Serum European IBC 0
17q22 (MPO) rs28730837 53 710 396 T/C 0.014 20.27 (0.04) 5.21 × 10212 Serum European IBC 21.6
17q22 (MPO) rs35897051 53 703 225 C/A 0.007 20.31 (0.06) 3.32 × 1028 Serum European IBC 63.9
17q22 (TRIM37) rs8081967 54 427 483 T/C 0.36 20.05 (0.01) 2.13 × 1026 Serum European IBC 37.5
1q42.13 (GALNT2) rs2144300 228 361 539 C/T 0.39 20.04 (0.01) 2.52 × 1027 Serum European IBC 0
1q31.3 (CFH) rs505102 194 886 125 G/A 0.71 20.15 (0.03) 1.05 × 1028 Serum AAs IBC 0
1q23.3 (DARC) rs2814778 157 441 307 G/A 0.78 20.21 (0.04) 6.48 × 1028 Serum AAs IBC 44.3
17q22 (C17orf71) rs6503905 54 642 236 A/G 0.37 20.06 (0.01) 2.94 × 10212 Plasma European GWAS 39.7
17q22 (RNF43) rs2680701 53 793 300 G/A 0.81 20.06 (0.01) 4.98 × 10210 Plasma European GWAS 42.4
17q22 (PPM1E) rs9911753 54 337 956 G/A 0.39 20.05 (0.01) 1.51 × 1029 Plasma European GWAS 44.7




rs12049351 227 784 624 C/G 0.79 20.05 (0.01) 1.08 × 1026 Plasma European GWAS 0
aSNP base pair (bp) positions are given according to NCBI build 36.1 of the reference human genome sequence.
bThe allele that lowers MPO levels is referred to as the effect allele. Units for betas are natural log-transformed circulating MPO levels in pmol/l.
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association of these SNPs with plasma MPO was attenuated
when conditioned on each other, with only rs6503905 exceeding
the genome-wide threshold for significance (P ¼ 9.07 × 1029)
when the analyses were conditioned on rs12940923 (Supple-
mentary Material, Table S7).
In addition to the chromosome 17q22 locus, we also observed
suggestive evidence for association of plasma MPO levels with
the region surrounding GALNT2 (Fig. 3B; Table 2; Supplemen-
tary Material, Table S6), although the lead SNP (rs12049351;
P ¼ 1.08 × 1026) differs from that identified for serum MPO
levels in the GWAS/IBC analyses (rs2144300). Rs12049351 is
not in LD with rs2144300 and is located 485 kb proximal to
GALNT2 in between ABCB10 and TAF5L. We also evaluated
the reciprocal association of all identified SNPs that were avail-
able across all genotyping platforms/datasets with both plasma
and serum MPO levels. SNPs identified in our GWAS for
plasma MPO levels also demonstrated varying degrees of asso-
ciation with serum MPO levels, whereas reciprocal associations
were not observed with plasma MPO levels (Supplementary Ma-
terial, Table S8). Since the SNPs on chromosome 17q22 and
rs12049351 at the ABCB10-TAF5L-GALNT2 locus demon-
strated association with both serum and plasma MPO levels
(Supplementary Material, Table S8), we also carried out a
meta-analysis across all independent subjects (combined n ¼
16 376). These analyses yielded P-values of 1.5 × 10211 and
5.4 × 1029 for association of rs6503905 and rs12049351, re-
spectively, with circulating MPO levels.
Functional effects of MPO-associated variants
To determine whether any of the identified SNPs were function-
al, we carried out biochemical and expression quantitative trait
locus (eQTL) analyses. For the rs800292 variant in CFH, we
measured serum levels of C3a-desArg, a downstream cleavage
product of complement activation, in a subset of 171 subjects
from the GeneBank cohort. These GeneBank subjects were
selected to represent equal numbers of the GG, AG, and AA gen-
otypes for rs800292 (n ¼ 57 each) and matched for age, sex and
CAD status. As shown in Figure 4, serum C3a-desArg levels
were significantly lower in carriers of the A allele compared
with GG homozygotes in a dose-dependent manner (P ¼
0.04). To further evaluate the functional effects of SNPs asso-
ciated with circulating MPO levels, we used previously gener-
ated microarray data in monocytes from 1467 subjects in the
GHS I and II cohorts (20). Significant and directionally consist-
ent cis eQTLs were observed with SNPs located on chromosome
17q22 and mRNA levels of MPO as well as several other genes in
this region, including RAD51C, SEPT4 and TRIM37 (Table 3).
For MPO and RAD51C, these associations remained significant
even after conditioning on the lead eQTL SNPs, which suggest
that this region may have pleiotropic effects on the expression
of multiple genes. No significant eQTL associations were
detected with SNPs at other loci that were associated with
serum or plasma MPO levels, including the CFH locus on
chromosome 1.
Figure 2. Regional plots for loci demonstrating a significant association with
serum MPO levels on chromosomes 1q31.3 (A), 6p21.32 (B), and 20p13 (C).
For each locus, a 1 Mb region is shown, centered on the lead SNP (purple
diamond). Genes in the selected intervals are indicated in the bottom panel.
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Effects of MPO-associated variants on the risk of CAD
To further investigate the significance of the loci for circulating
MPO levels, we evaluated the association of the identified SNPs
with prevalent CAD using the CARDIoGRAM consortium. This
consortium represents a GWAS meta-analysis of subjects with
history of CAD and is comprised of 22 000 cases and
65 000 controls. As shown in Table 4, none of the SNPs for
which CARDIoGRAM data were available showed significant
evidence of association with prevalent CAD.
DISCUSSION
Using meta-analyses of both GWAS and gene-centric data, we
identified distinct loci that were associated with serum and
plasma MPO levels. The most significant locus for serum
MPO levels in subjects of European ancestry was observed
with CFH on chromosome 1, which was replicated in AA sub-
jects. Of the three highly associated and linked CFH SNPs in sub-
jects of European ancestry (rs505102, rs800292 and rs6680396),
only rs505102 and rs800292 are in strong LD in AAs. As a result
of this different LD pattern, candidate causal SNPs responsible
for the association with lower serum MPO levels could include
rs505102, rs800292 or another SNP in LD with these variants.
Of these, rs800292 encodes a Val62Ile substitution in CFH
and has been previously associated with decreased risk of
age-related macular degeneration (AMD) in a Japanese popula-
tion (21). Other CFH variants have also been associated with
AMD (22–25), as well as meningococcal susceptibility (26),
IgA-induced nephropathy (27), atypical hemolytic uremic syn-
drome (HUS) (28), membranoproliferative glomerulonephritis
type II (29) and systemic lupus erythematosis (SLE) (30).
However, it is not known whether MPO plays a biological role
in these inflammatory diseases. In addition, the association of
the other disease-associated CFH variants with serum MPO
levels was attenuated when the analyses were conditioned on
rs800292, even though these SNPs are in weak LD (r2 , 0.30)
with rs800292 in subjects of European ancestry. Thus, while
several independent alleles at the CFH locus influence multiple
inflammatory-related disease phenotypes, the strong association
signal at this locus with serum MPO levels is primarily due to
rs800292 or other tightly linked variants.
Complement fixation is well known as a potent trigger of
leukocyte activation and degranulation, and serum generation
is associated with activation of protease cascades, including
complement proteins, such as C3a and C3b (31–33). Thus, an as-
sociation between a genetic variant for a complement protein and
serum MPO levels, but not plasma MPO levels, can be mechan-
istically rationalized and could be related to leukocyte activation
and partial degranulation during blood coagulation. A role for
the complement system in influencing serum MPO levels is
also supported by the results of our gene-centric analyses,
which identified an amino acid substitution in C2 (rs9332739)
for serum MPO levels that has also been previously associated
with AMD (34). The minor alleles of rs800292 in CFH and
rs9332739 in C2 protect against the development of AMD and
are associated with decreased serum MPO levels. The disease
protective Ile62 CFH variant (rs800292), which is located
within the SCR2 domain, has been shown to increase binding
of CFH to C3b and lead to greater inactivation of fluid-phase
and surface-bound C3b (35). Presumably, this would reduce com-
plement activation and leukocyte activation during serum separ-
ation, thereby leading to decreased MPO release from
neutrophils and/or monocytes. This notion is consistent with our
functional data, showing that the A allele of rs800292, which is
associated with decreased MPO levels, is associated with lower
serum levels of C3a-desArg, a cleavage product generated by
complement activation. In addition, clotting factors and proteases
that activate complement proteins and trigger degranulation of
MPO-rich phagocytes, such as neutrophils, are present in serum
but are mostly depleted in plasma. Therefore, CFH and C2 var-
iants that decrease complement activation, either through
increased CFH or reduced C2 activity, could be one potential
mechanism through which they lead to decreased MPO levels in
serum. By analogy, a common Asp42Gly variant of DARC has
been associated with serum, but not plasma, concentrations of
several pro-inflammatory chemokines (36). The mechanism
appears to be due to the release of these chemokines during
blood coagulation as a result of differential binding to DARC (36).
Whether the association of complement pathway variants
with AMD (and other inflammatory diseases) may be causally
related to enhanced MPO-related inflammatory processes
remains to be determined. MPO variants, including those identi-
fied herein, have not been reported to be associated with AMD,
meningococcal susceptibility, IgA-induced nephropathy, HUS,
membranoproliferative glomerulonephritis type II or SLE, sug-
gesting that circulating MPO levels may not play a causal role in
the pathogenesis of such inflammatory diseases. On the other
hand, MPO-induced oxidative damage to lipoproteins and the
vascular wall have been implicated in the development of athero-
sclerosis and its clinical sequelae, and systemic levels of MPO
predict cardiovascular risk. Oxidative stress and lipid peroxida-
tion are also involved in other chronic inflammatory diseases, in-
cluding AMD. In addition to regulating the complement system,
CFH is a major binding protein of malondialdehyde, a common
lipid peroxidation product (37). Taken together, these observa-
tions may mechanistically link stress-related oxidative tissue
injury to localized regulation of complement activity in a
variety of chronic inflammatory disorders.
In addition to loci containing genes of the complement system,
the region containing SIRPB2 also demonstrated genome-wide
significant association with serum MPO levels in subjects of
European ancestry. SIRPB2 is a member of the signal-regulatory
protein (SIRPs) family of transmembrane glycoproteins that are
expressed predominantly on myeloid cells and involved in the
regulation of innate immunity and complement receptor-
mediated phagocytosis (38). The role of SIRPB2 in antigen-
specific proliferation and activation of T-cells (39) may
provide an additional biological link for its association with
serum MPO levels. By comparison, the gene-centric analyses
in AA subjects identified a promoter variant of DARC
(rs2814778) that achieved near genome-wide significance for
association with serum MPO levels. Interestingly, the G allele
of this variant is highly prevalent in subjects of African
descent and results in the loss of the Duffy antigen on red
blood cells, which has been associated with resistance to
malaria infection (40) and low neutrophil count (41). Thus,
this is consistent with our observations that the A allele of
rs2814778 is associated with increased serum MPO levels
since MPO is most abundantly present in neutrophils.
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As a comparative analysis, we also carried out a GWAS for
plasma MPO levels in subjects of European descent. These
results identified multiple SNPs in a large 1 Mb interval
encompassing MPO on chromosome 17q22 that demonstrated
association with both plasma and serum MPO levels. These
results are further supported by our gene-centric analyses,
which identified rare MPO SNPs that were also associated
with serum MPO levels, including the previously reported
rs28730837 Ala332Val substitution (9). In contrast, the CFH
locus only demonstrated association with MPO levels in
serum. Based on the LD structure in the chromosome 17q22
region, the four SNPs that we identified are not tightly linked
to each other. However, with the exception of rs6503905,
which remained strongly associated with plasma MPO levels
after taking into account the effect of rs12940923, the associ-
ation signals with the remaining SNPs were attenuated in the
conditional analyses. Of note, rs12940923 is in relatively
strong LD (r2 ¼ 0.67) with a 2463 G.A promoter polymorph-
ism (rs2333227) in MPO that has previously been associated
with plasma MPO levels (42). The association of rs12940923
and rs6503905 with circulating MPO levels is also supported
by the directionally consistent and strong cis eQTLs these var-
iants exhibit with MPO expression, even after conditioning on
the lead eQTL SNP. Similar cis genetic effects were observed
on the expression of other genes at this locus (i.e. RAD51C) as
well. Taken together, these data indicate that several SNPs at
chromosome 17q22 contribute independently to circulating
MPO levels and suggest that this locus may contain a regulatory
region(s) with pleiotropic effects on gene expression.
Another interesting observation from our analyses of plasma
MPO levels is the suggestive association between circulating
MPO levels and variants in the vicinity of GALNT2. For
Figure3. Results of the GWASfor plasmaMPO levels in subjects ofEuropeanancestry.The Q–Q (A) and Manhattan (B) plotsare shownfor the meta-analysis of9260
subjects from the GeneBank, GHS I, GHS II, LURIC1 and LURIC2 cohorts. (C) Regional plot of a 1 Mb interval on chromosome 17q22 demonstrates several inde-
pendent SNPs that exceed the genome-wide threshold for significance. The bottom panel shows the LD pattern across this region using CEU data from HAPMAP.
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example, an intronic variant (rs2144300) of GALNT2, which we
identified in both GWAS and gene-centric analyses for serum
MPO levels, has previously been associated with lower HDL
levels (43). GALNT2 is involved in protein O-linked glycosyla-
tion and, while its role in regulating MPO levels is not immedi-
ately evident, it is interesting to note that MPO binds to HDL
within atherosclerotic lesions via apolipoprotein A-1 and cata-
lyzes HDL oxidation (44–46), thereby impairing its cardio-
protective properties. By comparison, the GWAS for plasma
MPO levels identified another SNP (rs12049351) located
485 kb proximal to GALNT2 in between ABCB10 and
TAF5L that was suggestively associated with plasma MPO
levels. Rs12049351 was also associated with serum MPO
levels whereas rs2144300 was not associated with plasma
MPO levels. These results suggest that specific alleles in this
region may control both serum and plasma MPO levels
whereas other independent variants are associated with only
levels in serum, possibly through a mechanism related to HDL
metabolism.
While the results of our analyses have revealed potentially
interesting loci that control circulating MPO levels, several lim-
itations of our study should be noted. First, circulating MPO
levels could be affected by environmental and/or transient
factors, such as physical activity or acute infections, which our
analyses did not take into account. Given the apparent effect of
serum generation on complement and leukocyte activation, dif-
ferences in handling and/or processing of blood samples in the
various cohorts may have also increased experimental variabil-
ity and led to additional confounders. Furthermore, GeneBank
recruited consecutive patients undergoing elective diagnostic
coronary angiography, which would enrich for subjects with
CAD, and lead to MPO levels that are on average higher
Fig. 3 Continued
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compared with the other population-based studies. This could
explain, in part, the variation seen in circulating MPO levels
across cohorts even when using the same assay, and the observed
heterogeneity in the association results for some of the identified
loci. However, these limitations are somewhat mitigated by our
use of a sample-weighted Z-score meta-analysis method and the
high level of significance obtained from the analyses.
In summary, our comprehensive genetic studies on two ethni-
cities identified several unique loci that are associated with either
serum or plasma MPO levels. These results indicate a potentially
prominent role for the complement system in influencing serum
MPO levels, presumably via leukocyte activation. By compari-
son, independent variants at the MPO locus were strongly asso-
ciated with plasma MPO levels but modestly associated with
serum levels. Despite the clinical association of both plasma
and serum MPO levels with both prevalent cardiovascular phe-
notypes and incident risk for major adverse cardiac events,
genetic variants associated with circulating MPO levels do not
show association with history of CAD in 80 000 subjects
from the CARDIoGRAM consortium. Additional studies will
be needed to gain a better understanding of the functional basis
for the association between circulating MPO levels and the iden-
tified variants in CFH and MPO, as well as to determine the clin-
ical implications for inflammatory diseases that could be
mediated in part through MPO-related activity.
MATERIALS AND METHODS
Study populations
The populations with serum and/or plasma MPO levels used in
the present study were the GeneBank, CARDIA, CHS, FHS,
MONICA/KORA, GHS and LURIC cohorts. Details of these
study populations are provided in the online Supplemental Mate-
rials section. The CARe Consortium is a National Heart Lung
and Blood Institute supported resource for analyses of the
association of genotypes with heart, lung and blood phenotypes
(47). All participants in each study provided a written informed
consent prior to being enrolled, and the studies were approved by
the Institutional Review Boards of the participating institutions.
Circulating measurements
Serum MPO levels were measured in the GeneBank, CARDIA,
CHS, FHS and MONICA/KORA cohorts, whereas plasma MPO
was measured in the GeneBank, GHS I and GHS II and LURIC
studies. The various assays used for these measurements in each
cohort are shown in Table 1. The CardioMPO assay is FDA and
EU cleared, and appropriate as an in vitro diagnostic test for use
in patient care. Serum levels of C3a-desArg, a downstream
cleave product of complement activation, were measured
using an OptEIA ELISA kit from BD Biosciences (San Diego,
CA, USA).
Genome-wide genotyping and imputation
The cohorts included in this meta-analysis of GWAS data used
different genotyping platforms: the Affymetrix Human SNP
Array 6.0 in the GeneBank, CARDIA, GHS I and II and
LURIC2 cohorts; the Affymetrix 500K Array Set for the FHS
and LURIC1 cohorts; and the Illumina HumanCNV370-Duo
for the CHS cohort. As a standard approach for facilitating
meta-analyses, all studies used their genotype data to impute un-
measured, autosomal SNPs using either the CEU data from
HapMap (release 22 or 24, build 36) or the 1000 Genomes
project. Imputation was performed using either the MACH
1.0.16, Beagle 3.2, or BIMBAM 0.99 programs. Imputation
results were filtered at an r2 threshold of 0.5 and a MAF threshold
of 0.01. For imputed genotypes, we used dosage information (i.e.
a value between 0.0 and 2.0 calculated using the probability of
each of the three possible genotypes) in the regression model
implemented in PLINK. Details of the genotyping platforms
and imputation methods for the GWAS are provided in
Table 1 and Supplementary Material, Table S1.
For gene-centric analyses, subjects with serum MPO mea-
surements from the CHS, FHS, CARDIA, and MONICA/
KORA cohorts were genotyped using the custom IBCv2 geno-
typing array that contains high SNP marker density and LD
coverage for 2100 genes related to cardiovascular, inflamma-
tory, hemostasis/coagulation, and metabolic phenotypes (48). A
total of 49 320 SNPs are present on the IBC array, including
15 000 SNPs in candidate genes that were not present in
HapMap. Additional details regarding SNP selection and the
tagging approach that was used have been described previously
(48). IBC genotyping was not available in participants from the
three cohorts with plasma MPO measurements.
Expression quantitative trait locus (eQTL) analysis
The functional effects of the identified SNPs on gene expression
in cis were determined using microarray data from monocytes of
1467 individuals in the GHS I and II cohorts, as described previ-
ously (20). Briefly, total RNA was isolated from purified mono-
cytes using RNeasy Mini kits (Qiagen, Hilden, Germany) and
hybridized to Illumina HT-12 v3 BeadChips (www.illumina.
com). Quality control filtering resulted in 22 305 genes that
Figure 4. Serum C3a-desArg levels as a function of CFH rs800292 genotype.
Serum levels of C3a-desArg are significantly lower in carriers of the A allele
compared with GG homozygotes in a dose-dependent manner. Data were mea-
sured in a subset of age-, sex- and CAD status-matched GeneBank subjects
and shown as untransformed mean+SE. The P-value was obtained using
linear regression analyses with natural-log transformation.
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were considered to be significantly expressed in monocytes and
tested for association using the available genotype data. When
the numbers of homozygotes for the minor allele of a SNP was
,30, they were grouped with heterozygotes. Association of
gene expression levels with SNPs was tested using the analysis
of variance models (20).
Statistical methods
SNPs were evaluated for association with natural log-transformed
circulating MPO levels using linear regression analyses, with ad-
justment for age and sex. Due to the difficulty of harmonizing
MPO assays across cohorts, SNP association results for each
ethnic group were combined using an effective sample-weighted
Z-score meta-analysis method, as implemented in the software
METAL (49), including a test for heterogeneity. Effect estimates
within and across all cohorts are expressed as beta coefficients
with standard errors. GWAS and gene-centric meta-analyses
for serum and plasma MPO levels (from the relevant cohorts)
were carried out separately. Differences in serum C3a-desArg
levels as a function of genotype were carried out with linear re-
gression using natural log-transformed values.
Associations with coronary artery disease (CAD)
The CAD Genome-wide Replication And Meta-Analysis (CAR-
DIoGRAM) Consortium represents a GWAS meta-analysis of
CAD comprising a discovery set of 22 000 cases and
65 000 controls (50). For each cohort in CARDIoGRAM, lo-
gistic regression was first used to test for association with
CAD assuming an additive genetic model with adjustment for
age and sex and taking into account the uncertainty of possibly
imputed genotypes. Subsequently, a meta-analysis was per-
formed separately for every SNP from each study that passed
the quality control criteria using a fixed-effects model with
inverse variance weighting (50). The results of this default
meta-analysis were used to determine whether SNPs affecting
circulating MPO levels were also associated with CAD.
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Table 4. MPO-associated SNPs and risk of CAD in the CARDIoGRAM consortium
MPO Levels (Analysis) Locus (Nearest Gene(s)) SNP Allele Frequency OR (95% CI) P-value n
Serum (GWAS) 1q31.3 (CFH) rs800292 G 0.74 0.99 (0.96–1.03) 0.71 78 841
Serum (GWAS) 1q42.13 (GALNT2) rs2144300 C 0.40 1.03 (1.0–1.06) 0.06 83 756
Serum (GWAS) 8p21.3 (ATP6V1B2-LZTS1) rs1390943 G 0.33 0.99 (0.96–1.02) 0.57 78 176
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Plasma (GWAS) 1q42.13 (ABCB10-TAF5L-URB2-GALNT2) rs12049351 C 0.80 0.97 (0.94–1.01) 0.12 83 470
Results are only shown for index SNPs or proxy variants that were available in the CARDIoGRAM Consortium.
aUsed as proxy for rs6503905 (r2 ¼ 0.70).
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